{"disease":{"id":"diffuse-astrocytoma-idh-mutant","name":"diffuse astrocytoma idh mutant"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05190172","title":"PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas","phase":"NA","overall_status":"RECRUITING","enrollment_count":225,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06047379","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":134,"lead_sponsor_name":"Neonc Technologies, Inc.","has_results":false},{"nct_id":"NCT06860594","title":"Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma","phase":"PHASE1","overall_status":"SUSPENDED","enrollment_count":30,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}